Brauer Jeremy A, Alabdulrazzaq Hamad, Bae Yoon-Soo Cindy, Geronemus Roy G
J Drugs Dermatol. 2015 Nov;14(11):1262-7.
We investigated the safety, tolerability and efficacy of a low energy low density, non-ablative fractional 1,927-nm laser in the treatment of facial photodamage, melasma, and post inflammatory hyperpigmentation.
Prospective non-randomized trial.
Single center, private practice with a dedicated research department.
Subjects with clinically diagnosed facial photodamage, melasma, or post inflammatory hyperpigmentation.
Subjects received four to six treatments at 14-day intervals (+/- 3 days) with a low energy low density non-ablative fractional 1,927-nm laser (Solta Hayward, CA) with an energy level of 5 mJ, and density coverage of either 5%, 7.5%, or 10%, with a total of up to 8 passes.
Blinded assessment of clinical photos for overall improvement at one and three months post final treatment. Investigator improvement scores, and subject pain and satisfaction scores for overall improvement were recorded as well.
We enrolled 23 subjects, average age 45.0 years (range, 25-64 years), 22 with Fitzpatrick Skin Types I-IV and 1 with Type VI, with facial photodamage, melasma, or post inflammatory hyperpigmentation. Approximately 55% of subjects reported marked to very significant improvement at one and three months post final treatment. Blinded assessment of photography of 20 subjects revealed an average of moderate improvement at one-month follow up and mild to moderate improvement at three months. Average subject pain score was 3.4/10 during treatment.
Favorable outcomes were demonstrated using the low energy low density, non-ablative fractional 1,927-nm laser in facial resurfacing for photodamage, melasma, and post inflammatory hyperpigmentation. Results were maintained at the 3-month follow up, as demonstrated by investigator and subject assessments, as well as blinded evaluations by three independent dermatologists utilizing photographs obtained from a standardized facial imaging device.
我们研究了低能量低密度非剥脱性1927纳米分数激光治疗面部光损伤、黄褐斑和炎症后色素沉着的安全性、耐受性和疗效。
前瞻性非随机试验。
单中心，设有专门研究部门的私人诊所。
临床诊断为面部光损伤、黄褐斑或炎症后色素沉着的受试者。
受试者接受4至6次治疗，间隔14天（±3天），使用能量水平为5 mJ、密度覆盖率为5%、7.5%或10%的低能量低密度非剥脱性1927纳米分数激光（加利福尼亚州索塔海沃德市），总共最多8次照射。
在最后一次治疗后1个月和3个月对临床照片进行盲法评估以判断整体改善情况。记录研究者的改善评分以及受试者对整体改善的疼痛和满意度评分。
我们招募了23名受试者，平均年龄45.0岁（范围25 - 64岁），其中22名菲茨帕特里克皮肤分型为I - IV型，1名VI型，患有面部光损伤、黄褐斑或炎症后色素沉着。约55%的受试者在最后一次治疗后1个月和3个月报告有显著至非常显著的改善。对20名受试者照片的盲法评估显示，1个月随访时平均为中度改善，3个月时为轻度至中度改善。治疗期间受试者平均疼痛评分为3.4/10。
使用低能量低密度非剥脱性1927纳米分数激光对面部进行光损伤、黄褐斑和炎症后色素沉着的皮肤磨削术取得了良好效果。研究者和受试者评估以及三名独立皮肤科医生利用标准化面部成像设备获取的照片进行的盲法评估均表明，3个月随访时结果得以维持。
